TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
AVIR

Atea Pharmaceuticals Inc

Healthcare · Biotechnology

5.30$ +2.1% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Atea Pharmaceuticals Inc (AVIR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.2% of the shares are freely tradable; institutional investors hold 80.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 80.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 13.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 75.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 12.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 80Mio.

Largest Shareholders

Institutions

Institutions AVIR
Name Stake (%) Shares Change (%) Date
FMR Inc 14.90 11,950,772 +23.5 03/31/2026
BlackRock Inc 10.52 8,435,437 -0.7 03/31/2026
BML Capital Management LLC 8.67 6,952,330 -1.5 06/30/2026
TANG CAPITAL MANAGEMENT LLC 6.00 4,814,700 +0.0 03/31/2026
Vanguard Capital Management, LLC 4.05 3,246,124 +0.0 03/31/2026
Bain Capital Life Sciences Investors, LLC 2.94 2,360,638 -5.0 03/31/2026

Funds

Funds AVIR
Name Stake (%) Shares Change (%) Date
Fidelity Growth Compy Commingled Pl S 8.16 6,543,395 +0.0 07/31/2026
Fidelity Growth Company Fund 3.86 3,099,127 +0.0 07/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.53 2,032,268 +0.0 07/31/2026
iShares Russell 2000 ETF 2.25 1,807,845 -0.6 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?